Trial reportMicrobial biotechnology2026
Effects of Bifidobacterium animalis Subsp. Lactis CP-9 on Gut Microbiota and Immune Functions in Healthy Infants.
Trial report in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Infancy represents a critical period for growth and development, during which the gut microbiota and its metabolites play essential roles in nutrient absorption and maintaining health. Therefore, it is of great significance to evaluate the safety and gut microbiota-modulating effects of specific probiotics in healthy infants. This study aimed to investigate the effect of Bifidobacterium animalis subsp. lactis CP-9 strain (CP-9) on healthy infants aged 6 to 36 months and its relationship with growth patterns and multidimensional indicators. In this randomized, double-blind, placebo-controlled trial, healthy infants were randomly assigned to receive CP-9 or placebo for 3 months. Safety, growth parameters, complete blood counts (CBC), immunological markers and faecal microbiota were assessed before and after the intervention. All infants exhibited age-appropriate growth in height and head circumference during the study. The CP-9 strain significantly increased gut Bifidobacterium abundance and regulated the microbiota-mediated polyunsaturated fatty acids biosynthesis pathway. Haematological and systemic inflammatory markers remained within normal ranges and no treatment-related adverse changes were detected during the 3-month intervention period. Moreover, CP-9 improved stool characteristics and gastrointestinal tolerability, with no increase in the incidence of respiratory allergies, skin allergies, respiratory infections, or fever, which further confirmed its safety. These findings suggested that CP-9 supplementation resulted in significant enrichment of Bifidobacterium, a beneficial gut bacterium and had no detectable adverse effects on the measured physiological parameters. Consequently, the intervention raised no detectable safety concerns in healthy infants under the conditions of this study. Given this, CP-9 is a probiotic that does not show any obvious short-term safety signals for infants aged 6 to 36 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.